417 related articles for article (PubMed ID: 34129817)
1. Innate immune cells in the tumor microenvironment.
Li MO; Wolf N; Raulet DH; Akkari L; Pittet MJ; Rodriguez PC; Kaplan RN; Munitz A; Zhang Z; Cheng S; Bhardwaj N
Cancer Cell; 2021 Jun; 39(6):725-729. PubMed ID: 34129817
[TBL] [Abstract][Full Text] [Related]
2. Contribution to Tumor Angiogenesis From Innate Immune Cells Within the Tumor Microenvironment: Implications for Immunotherapy.
Albini A; Bruno A; Noonan DM; Mortara L
Front Immunol; 2018; 9():527. PubMed ID: 29675018
[TBL] [Abstract][Full Text] [Related]
3. Tumor Immune Microenvironment and Its Related miRNAs in Tumor Progression.
Xing Y; Ruan G; Ni H; Qin H; Chen S; Gu X; Shang J; Zhou Y; Tao X; Zheng L
Front Immunol; 2021; 12():624725. PubMed ID: 34084160
[TBL] [Abstract][Full Text] [Related]
4. Modulation of tumor microenvironment for immunotherapy: focus on nanomaterial-based strategies.
Liu Y; Guo J; Huang L
Theranostics; 2020; 10(7):3099-3117. PubMed ID: 32194857
[TBL] [Abstract][Full Text] [Related]
5. Activities of stromal and immune cells in HPV-related cancers.
Barros MR; de Melo CML; Barros MLCMGR; de Cássia Pereira de Lima R; de Freitas AC; Venuti A
J Exp Clin Cancer Res; 2018 Jul; 37(1):137. PubMed ID: 29976244
[TBL] [Abstract][Full Text] [Related]
6. Diamonds in the Rough: Harnessing Tumor-Associated Myeloid Cells for Cancer Therapy.
Clappaert EJ; Murgaski A; Van Damme H; Kiss M; Laoui D
Front Immunol; 2018; 9():2250. PubMed ID: 30349530
[TBL] [Abstract][Full Text] [Related]
7. Tumor promoting capacity of polymorphonuclear myeloid-derived suppressor cells and their neutralization.
Groth C; Weber R; Lasser S; Özbay FG; Kurzay A; Petrova V; Altevogt P; Utikal J; Umansky V
Int J Cancer; 2021 Nov; 149(9):1628-1638. PubMed ID: 34224592
[TBL] [Abstract][Full Text] [Related]
8. Mast cells as targets for immunotherapy of solid tumors.
Oldford SA; Marshall JS
Mol Immunol; 2015 Jan; 63(1):113-24. PubMed ID: 24698842
[TBL] [Abstract][Full Text] [Related]
9. Innate immune mediators in cancer: between defense and resistance.
Berraondo P; Minute L; Ajona D; Corrales L; Melero I; Pio R
Immunol Rev; 2016 Nov; 274(1):290-306. PubMed ID: 27782320
[TBL] [Abstract][Full Text] [Related]
10. Exosomes as mediators of immune regulation and immunotherapy in cancer.
Kugeratski FG; Kalluri R
FEBS J; 2021 Jan; 288(1):10-35. PubMed ID: 32910536
[TBL] [Abstract][Full Text] [Related]
11. Type I interferon-mediated tumor immunity and its role in immunotherapy.
Yu R; Zhu B; Chen D
Cell Mol Life Sci; 2022 Mar; 79(3):191. PubMed ID: 35292881
[TBL] [Abstract][Full Text] [Related]
12. The Contribution of the Immune System in Bone Metastasis Pathogenesis.
Xiang L; Gilkes DM
Int J Mol Sci; 2019 Feb; 20(4):. PubMed ID: 30823602
[TBL] [Abstract][Full Text] [Related]
13. Plasticity in Pro- and Anti-tumor Activity of Neutrophils: Shifting the Balance.
Furumaya C; Martinez-Sanz P; Bouti P; Kuijpers TW; Matlung HL
Front Immunol; 2020; 11():2100. PubMed ID: 32983165
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic Approaches Targeting the Natural Killer-Myeloid Cell Axis in the Tumor Microenvironment.
Carnevalli LS; Ghadially H; Barry ST
Front Immunol; 2021; 12():633685. PubMed ID: 33953710
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-33 in Malignancies: Friends or Foes?
Shen JX; Liu J; Zhang GJ
Front Immunol; 2018; 9():3051. PubMed ID: 30619376
[TBL] [Abstract][Full Text] [Related]
16. Mesenchymal Stem Cell: A Friend or Foe in Anti-Tumor Immunity.
Harrell CR; Volarevic A; Djonov VG; Jovicic N; Volarevic V
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830312
[TBL] [Abstract][Full Text] [Related]
17. Targeting Innate Immunity in Breast Cancer Therapy: A Narrative Review.
Ye Y; Xu C; Chen F; Liu Q; Cheng N
Front Immunol; 2021; 12():771201. PubMed ID: 34899721
[TBL] [Abstract][Full Text] [Related]
18. Innate myeloid cells in the tumor microenvironment.
Duhan V; Smyth MJ
Curr Opin Immunol; 2021 Apr; 69():18-28. PubMed ID: 33588308
[TBL] [Abstract][Full Text] [Related]
19. Myeloid cells as orchestrators of the tumor microenvironment: novel targets for nanoparticular cancer therapy.
Tuettenberg A; Steinbrink K; Schuppan D
Nanomedicine (Lond); 2016 Oct; 11(20):2735-2751. PubMed ID: 27658725
[TBL] [Abstract][Full Text] [Related]
20. Histamine in cancer immunology and immunotherapy. Current status and new perspectives.
Sarasola MP; Táquez Delgado MA; Nicoud MB; Medina VA
Pharmacol Res Perspect; 2021 Oct; 9(5):e00778. PubMed ID: 34609067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
